7.20MMarket Cap-0.63P/E (TTM)
0.200High0.175Low2.33MVolume0.200Open0.185Pre Close428.90KTurnover7.06%Turnover RatioLossP/E (Static)41.12MShares0.97052wk High1.50P/B5.78MFloat Cap0.15152wk Low--Dividend TTM33.04MShs Float21.420Historical High--Div YieldTTM13.54%Amplitude0.151Historical Low0.183Avg Price1Lot Size
Coeptis Therapeutics Stock Forum
📊⚡️📊
Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries
1 minute ago, 5:15 AM PST
Via PR Newswire
The Acquisition of NexGenAI Affiliates Network Expands Company's Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth
WEXFORD, Pa. , Dec. 3, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"...
Dow Jones· just
Coeptis Therapeutics Announces Phase 1 Data on Dvx201 for Covid-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Developmen
Coeptis Therapeutics announced the acceptance of Phase 1 study results for DVX201, an allogeneic natural killer (NK) cell therapy, in Molecular Therapy Methods and Clinical Development. The study evaluated DVX201 for treating hospitalized COVID-19 patients at high risk for disease progression. Key f...
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
Coeptis Therapeutics Holdings (Nasdaq: COEP) has expanded its license agreement with Deverra Therapeutics to include pandemic preparedness and emergency use applications for their allogeneic natural killer (NK) cell technology. The expanded license now covers the use of unmodified NK cells for treating viral infections, pandemic-related illnesses, ...
Coeptis Therapeutics Expands License Agreement With Deverra to Include Pandemic Preparedness, and Emergency
3 MINUTES AGO, 7:07 AM EDT
VIA PR NEWSWIRE
No comment yet